CA Patent

CA2510228C — 25-so2-substituted analogs of 1.alpha.,25-dihydroxyvitamin d3

Assigned to Cytochroma Inc · Expires 2012-10-30 · 14y expired

What this patent protects

The present invention provides novel analogs of 1.alpha.,25-dihydroxyvitamin of formula Ia and Ib: (see formula Ia) (see formula Ib), compositions comprising these compounds and methods of using these compounds as selective inhibitors of CYP24. In particular, the compounds of t…

USPTO Abstract

The present invention provides novel analogs of 1.alpha.,25-dihydroxyvitamin of formula Ia and Ib: (see formula Ia) (see formula Ib), compositions comprising these compounds and methods of using these compounds as selective inhibitors of CYP24. In particular, the compounds of the invention are useful for treating diseases which benefit from a modulation of the levels of 1.alpha.,25-dihydroxyvitamin D3, for example, cell-proliferative disorders.

Drugs covered by this patent

Patent Metadata

Patent number
CA2510228C
Jurisdiction
CA
Classification
Expires
2012-10-30
Drug substance claim
No
Drug product claim
No
Assignee
Cytochroma Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.